The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α v β 3 ) Antibody in Patients with Metastatic Cancer
Abstract
The angiogenic response of a progressing malignancy is characterized by a shift in the balance of stimulatory and inhibiting factors of angiogenesis. Recognition of the regulated steps in tumor angiogenesis provides unique targets for developing anti-tumor therapy. Vitaxin is a humanized monoclonal antibody, which has specificity for the integrin alpha v beta 3 (vitronectin receptor). This antibody can impair the vascular response of endothelial cell growth factors in vitro and inhibit tumor cell mediated angiogenesis in pre-clinical animal models. Patients with metastatic cancer who failed standard therapy received intravenous doses of 10, 50 or 200 mg in cohorts of three patients. The unlabeled dose of Vitaxin was infused on days 0 and 21 of a treatment cycle. All patients received a pre-therapy imaging dose of 1 mg of Tc-99m Vitaxin with gamma camera imaging studies. There was no significant toxicity noted in these three dose levels. There were no objective anti-tumor responses. Three patients received two cycles of therapy and had stable disease at day 85 when taken off study. Radioimaging of tumor vasculature was unsuccessful although one patient with alpha v beta 3 positive melanoma had imaging of tumor sites. There was no immune response to Vitaxin in any patient. Patients receiving 10 mg doses of Vitaxin had poor plasma recovery of injected doses and brief circulation in plasma. Doses of 50 and 200 mg had plasma recovery that better approximated the predicted levels in plasma and circulation half-lives of approximately 7 days. This data suggests that an every three-week schedule of Vitaxin at doses of 200 mg (2.5-3.5 mg/kg) can maintain circulating levels of antibody with little or no toxicity. Future studies will be challenged to define anti-tumor activity in malignancy or appropriate surrogates of anti-tumor effect and explore escalating doses and alternate schedules of administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
Brooks, P. C., Montgomery, A. M. P., Rosenfeld, M., Reisfeld, R. A., Hu, T., Klier, G., & Cheresh, D. A. (1994) · Cell · doi:10.1016/0092-8674(94)90007-8 · Cited by 2,262
Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683
Cited by
Peptide-Labeled Near-Infrared Quantum Dots for Imaging Tumor Vasculature in Living Subjects
Cai, W., Shin, D.-W., Chen, K., Gheysens, O., Cao, Q., Wang, S. X., Gambhir, S. S., & Chen, X. (2006) · Nano Letters · doi:10.1021/nl052405t · Cited by 948
Immunogenicity of engineered antibodies
Hwang, W. Y. K., & Foote, J. (2005) · Methods · doi:10.1016/j.ymeth.2005.01.001 · Cited by 630
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Signalling via integrins: Implications for cell survival and anticancer strategies
Hehlgans, S., Haase, M., & Cordes, N. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.09.001 · Cited by 373
Integrin αvβ3‐targeted cancer therapy
Liu, Z., Wang, F., & Chen, X. (2008) · Drug Development Research · doi:10.1002/ddr.20265 · Cited by 323
Metadata
- Authors
- Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., & LoBuglio, A. F.
- Venue
- Cancer Biotherapy and Radiopharmaceuticals
- Publisher
- SAGE Publications
- Published
- 2001-04
- Volume
- 16
- Issue
- 2
- Pages
- 125-132
- ISSN
- 1084-9785 (ISSN-L)
- 1557-8852
- OpenAlex
- W2003366243
- Cited by
- 190
- References
- 2
- FWCI
- 4.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α v β 3 ) Antibody in Patients with Metastatic Cancer. https://app.cochat.ai/papers/10.1089/108497801300189218
- The paper
- Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., & LoBuglio, A. F. (2001). A Pilot Trial of Vitaxin, A Humanized Anti-Vitronectin Receptor (anti α v β 3 ) Antibody in Patients with Metastatic Cancer. Cancer Biotherapy and Radiopharmaceuticals. https://doi.org/10.1089/108497801300189218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.